The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1104
May 14, 2001
View Complete Issue         Table of Contents 2019 
Erythropoietin (Procrit; Epogen) Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Erythropoietin (Procrit; Epogen) Revisited
May 14, 2001 (Issue: 1104)
Use of epoetin alfa, a recombinant human erythropoietin, is being promoted directly to consumers in vague advertisements that promise renewed energy and improved work capacity. Epoetin is approved by the FDA for treatment of anemia due to chronic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Erythropoietin (Procrit; Epogen) Revisited
Article code: 1104b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.